CDK4/6 inhibitors in HR‑positive/HER2‑negative breast cancer: a scoping review of randomised clinical trials
Introduction. Breast cancer is the most common malignancy in women and a leading cause of cancer mortality. The HR-positive/HER2-negative subtype accounts for most cases and is characterized by initial endocrine sensitivity followed by resistance. This study aimed to map and interpret randomized clinical trial evidence on the efficacy and safe...
By SANJA STOJANOVIĆ GAGOVIĆ, NIKOLINA DUKIĆ, JELENA VLADIČIĆ MAŠIĆ, DRAGANA STUPAR, NEMANJA KOVAČ, SNEŽANA ZEČEVIĆ